Search research articles
Contact Us
Filters
Showing results (51-60 of 88) with videos related to
Page
of 9
Sort By:
Biomedicines
|
October 28, 2023
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
Christopher D Sarsons, Dean Gilham, Laura M Tsujikawa, et al.
Atherosclerosis
|
May 24, 2016
Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57]
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 14, 2008
Attention bias toward threat in pediatric anxiety disorders
Amy Krain Roy, Roma A Vasa, Maggie Bruck, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 14, 2017
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
Stephen J Nicholls, Kausik K Ray, Jan O Johansson, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
August 30, 2018
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial
Daisuke Shishikura, Yu Kataoka, Satoshi Honda, et al.
Kidney International Reports
|
June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines
|
June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
International Immunopharmacology
|
March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
Li Fu, Dean Gilham, Stephanie C Stotz, et al.
Pharmacology Research & Perspectives
|
April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
JAMA
|
March 29, 2020
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
Kausik K Ray, Stephen J Nicholls, Kevin A Buhr, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 88) with videos related to
Sort By:
Page
of 9
Biomedicines
|
October 28, 2023
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
Christopher D Sarsons, Dean Gilham, Laura M Tsujikawa, et al.
Atherosclerosis
|
May 24, 2016
Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57]
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 14, 2008
Attention bias toward threat in pediatric anxiety disorders
Amy Krain Roy, Roma A Vasa, Maggie Bruck, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 14, 2017
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
Stephen J Nicholls, Kausik K Ray, Jan O Johansson, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
August 30, 2018
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial
Daisuke Shishikura, Yu Kataoka, Satoshi Honda, et al.
Kidney International Reports
|
June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines
|
June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
International Immunopharmacology
|
March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
Li Fu, Dean Gilham, Stephanie C Stotz, et al.
Pharmacology Research & Perspectives
|
April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
JAMA
|
March 29, 2020
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
Kausik K Ray, Stephen J Nicholls, Kevin A Buhr, et al.
Page
of 9